After a $387.5 million hack on Bitget, attackers routed stolen funds through THORChain, generating $573,226 in liquidity fees. THORChain co-founder Chad Barraford suggested the protocol's Treasury consider returning some developer fund income from these fees to Bitget, which has pledged to cover the losses. The dispute highlights challenges in THORChain's fee distribution and governance, as the protocol refuses to block attacker wallets due to its design. Barraford plans to raise the refund proposal with the Treasury amid ongoing debates on how to handle the hacked funds within the network's validator system.
THORChain and Bitget fee dispute provide context for crypto market conditions. For readers following major cryptocurrencies on Pluang, as of Oct 07, 2026 04:41 WIB: 9 out of 50 major cryptocurrencies rose, 40 fell. EGLD price was Rp79.645 with a 1-day change of -4.07%, SAND price was Rp1.184 with a 1-day change of -4.02%, and ZIL price was Rp63 with a 1-day change of -3.81%.
Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...
U.S. spot Solana ETFs experienced $3.7 million in net outflows on October 6, marking the second consecutive day of withdrawals. The Grayscale Solana Trust was the main contributor to this decline, while six other funds showed no net flow. Although th...
Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...
On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...
On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...
